# Progress Note 06 — Preventive Visit

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Wilma Rudolph (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML036-SYN-TD
- Date: 1994-10-29
- Fictional facility: St. Posthumous Health Center
- Fictional author: Gloria Haynes-Whitaker, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Preventive Visit
- Services: CPT 99396 (periodic preventive medicine, established patient, age 40 to 64) with CPT 99497 (advance care planning), both on the same day

## Chief complaint

Periodic adult preventive visit. **S**

## History of present illness

Ms. Rudolph is a 54-year-old hospital executive and former Olympic sprinter with an IDH-wildtype, MGMT-methylated glioblastoma of the left frontal lobe, treated with gross total resection and six weeks of radiotherapy with daily temozolomide, who comes for her yearly preventive visit on day 21 of her first adjuvant temozolomide cycle. The MRI three weeks ago showed no progression. She took the five doses of temozolomide without vomiting, using ondansetron before each. She wears the tumor-treating fields device about 19 hours a day; the scalp under the arrays is a little pink but not broken. She is tired by mid-afternoon but works mornings from home. She has had no headache, seizure, change in speech, weakness or fall. Her right hand is back to normal for writing. She walks most days with the cane she keeps for uneven ground. **S**

| Element | Detail |
|---|---|
| Visit | Periodic adult preventive visit, age 54 |
| Glioblastoma | No progression on the post-chemoradiation MRI; adjuvant cycle 1, day 21 |
| Tumor-treating fields | About 19 hours a day; mild scalp redness |
| Mood | PHQ-2 1 |

## Health risk assessment

Completed by the patient on the clinic's paper form in the waiting room and reviewed with her by Dr. Haynes-Whitaker. **S**

| Domain | Finding |
|---|---|
| Self-rated health | Fair; tired in the afternoons |
| Psychosocial | Close to her family and friends; still working part days; keeps her spirits up with time with her family and her foundation's young athletes |
| Substance use | No tobacco; no alcohol since surgery; no drug use |
| Physical activity | Walks 20 to 30 minutes most days; home exercises from physical therapy three times a week |
| Nutrition | Appetite fair; eats small meals; weight steady |
| Sleep | Seven to eight hours with the device on; a short nap after lunch |
| Falls and home safety | No falls; grab bars and night lights in place; cane for uneven ground |
| Driving | Not driving since the first symptoms; family and friends drive her |
| Activities of daily living | Independent in all |
| Seat belt and smoke alarms | Always wears a seat belt; smoke alarms tested |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Afternoon fatigue; no fever or weight loss |
| Eyes | Negative | No double or blurred vision |
| Ears, nose, mouth, and throat | Negative | No mouth sores or sore throat |
| Cardiovascular | Negative | No chest pain or leg swelling |
| Respiratory | Negative | No cough or breathlessness |
| Gastrointestinal | Negative | No nausea now, vomiting, diarrhea or constipation |
| Genitourinary | Negative | No urinary symptoms; no vaginal bleeding |
| Breast | Negative | No lump or nipple change |
| Musculoskeletal | Negative | No new weakness, muscle pain or joint pain in either leg |
| Integumentary | Positive | Mild pinkness of the scalp under the device arrays; no blisters or broken skin |
| Neurological | Negative | No headache, seizure, numbness or speech change |
| Hematologic and lymphatic | Negative | No bruising or bleeding |
| Psychiatric | Negative | Mood steady; PHQ-2 1 |

13 systems reviewed. **S**

## Current medications

- Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for headache, no more than 3 g a day **S**
- Sulfamethoxazole 800 mg and trimethoprim 160 mg oral tablet, one tablet three times a week (Monday, Wednesday and Friday) to prevent Pneumocystis pneumonia **S**
- Ondansetron 8 mg oral tablet, one tablet 30 to 60 minutes before each temozolomide dose, and every 8 hours as needed for nausea **S**
- Temozolomide 140 mg oral capsule, 280 mg (150 mg/m2) by mouth at bedtime on days 1 to 5 of each 28-day cycle, adjuvant cycle 1 of 6 **S**

## Allergies

- No known allergy **S**

## Objective

BP 118/72 mmHg; pulse 76 bpm; respirations 14/min; temperature 36.5 °C; oxygen saturation 99% on room air; weight 66.9 kg; BMI 20.6 kg/m². All vital signs are synthetic.

Hemoglobin: 11.8 g/dL (low); White cell count: 3.4 10*3/uL (low); Absolute neutrophil count: 1.9 10*3/uL; Absolute lymphocyte count: 0.6 10*3/uL (low); Platelets: 121 10*3/uL (low); ALT: 33 U/L; AST: 29 U/L; PHQ-2: 1. All results are synthetic.

## Change since baseline

- Hemoglobin: 13.1 g/dL at baseline, 11.8 g/dL (low) at this visit **S**
- White cell count: 7.1 10*3/uL at baseline, 3.4 10*3/uL (low) at this visit **S**
- Platelets: 262 10*3/uL at baseline, 121 10*3/uL (low) at this visit **S**
- PHQ-2: 1 at baseline, 1 at this visit **S**

## Immunizations given today

- Influenza vaccine, inactivated, trivalent, preservative free, this season **S**
- Pneumococcal conjugate vaccine PCV20 **S**
- Recombinant zoster vaccine, dose 1 of 2 **S**

## Physical examination

| System | Finding |
|---|---|
| Constitutional | Well; weight 66.9 kg; blood pressure 118/72; pulse 76; temperature 36.5 °C |
| Head | Craniotomy incision healed; hair loss over the radiation field; scalp under the arrays mildly pink, intact |
| Mouth | No ulcers or thrush |
| Breasts | Clinical breast examination with a chaperone, at her choice: no masses, skin or nipple changes, or axillary nodes |
| Cardiovascular | Regular rhythm; no murmur |
| Respiratory | Clear |
| Abdomen | Soft, non-tender |
| Extremities | No leg swelling; calves soft and non-tender; left calf slightly smaller than the right, as before |
| Skin | No bruising or petechiae |
| Neurological | Fluent speech; strength full in all four limbs; steady gait; Timed Up and Go 9 seconds |
| Psychiatric | Warm, engaged and direct |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Periodic adult preventive visit completed**. Health risk assessment reviewed and the prevention plan updated. Her screening for breast, cervical and colorectal cancer is up to date, and we agreed to decide about the next rounds of screening together when they fall due, in light of her treatment. Influenza, PCV20 and the first recombinant zoster dose given today: inactivated vaccines are safe during temozolomide, though her response may be blunted. A COVID-19 vaccine this season is due at her pharmacy. She declined lipid screening for now while she is on treatment. **S**
   - Second zoster dose in one to two months.
   - COVID-19 vaccine this season.
   - Dental and eye examinations this year.
   - Next preventive visit in one year.
2. **Glioblastoma, IDH-wildtype, CNS WHO grade 4, MGMT methylated, on adjuvant temozolomide and tumor-treating fields** (C71.1). Day-21 blood count: neutrophils 1.9 and platelets 121, both above the thresholds for the next cycle, so cycle 2 can start on day 29, and the dose can rise to 200 mg/m2 as the label allows when the cycle 1 nadir and tolerance are this good. ALT 33 and AST 29 U/L: the cycle 1 liver tests, drawn today with the count rather than at the midpoint of the cycle, are normal (the deviation is recorded in the cycle 1 note). Scalp redness under the arrays is grade 1. **S**
   - Cycle 2 of temozolomide at 200 mg/m2 on day 29 if counts are still adequate.
   - Topical corticosteroid cream for the scalp between array changes; shift the arrays slightly at each change.
   - Blood count weekly until counts recover, then on day 22 of each cycle.
3. **Lymphopenia from temozolomide, grade 2** (D72.810). Absolute lymphocytes 0.6; Pneumocystis prophylaxis continues. **S**
   - Continue sulfamethoxazole-trimethoprim three times a week.
4. **Late effects of childhood poliomyelitis** (B91). No new weakness, fatigue beyond what treatment explains, or pain in the legs to suggest post-polio syndrome; walking safely. **S**
   - Home exercises; check leg strength at each visit.

## Personalized prevention plan

A written copy was given to the patient. **S**

| Service | Status | Detail |
|---|---|---|
| Blood pressure screening | Completed today | 118/72 mmHg |
| Depression screening | Completed today | PHQ-2 score 1; PHQ-9 6 three weeks ago |
| Unhealthy alcohol use screening | Completed today | No alcohol since surgery |
| Tobacco use | Completed today | Never |
| Breast cancer screening | Up to date | Mammogram every two years from 40 to 74; last screening mammogram about a year ago, normal; next to be decided with her when due |
| Cervical cancer screening | Up to date | Cytology with HPV testing about two years ago, negative; next due in about three years |
| Colorectal cancer screening | Up to date | Colonoscopy at 50, normal; next due at 60 |
| Diabetes screening | Up to date | A1c 5.6% before steroids; glucose 91 mg/dL three weeks ago, off steroids |
| Lipid screening | Declined | Declined for now: not drawn today, by her choice, while she is on cancer treatment; to be revisited at the next preventive visit |
| HIV, hepatitis B and hepatitis C screening | Up to date | All negative before temozolomide |
| Osteoporosis screening | Not indicated | Postmenopausal at 54; dexamethasone for under two months and no fracture, so her estimated fracture risk is below the threshold for bone density testing; to be reconsidered if steroids are needed again or she falls |
| Fall risk and mobility | Completed today | No falls; Timed Up and Go 9 seconds; home exercises and home safety measures in place |
| Lung cancer screening | Not indicated | Never smoker |
| Influenza, pneumococcal and zoster vaccines | Completed today | Inactivated influenza vaccine, PCV20 and recombinant zoster dose 1 given today; no live vaccines during chemotherapy |
| COVID-19 vaccine, this season | Due | At her pharmacy, at least a few days apart from the next temozolomide cycle if she prefers |
| Dental and eye examinations | Due | Dental review and an eye examination advised this year |

## Advance care planning

Voluntary advance care planning discussion of about 20 minutes, with her consent, reviewing the advance directive she completed with the palliative care team last month. She wants treatment aimed at controlling the tumor for as long as it lets her live in a way she values, being at home and with the people she loves, and wants to be told plainly when that balance changes. Her named health care agent is recorded in the confidential part of the chart and is not named here. She asked that information about her health go only to the people she names. To be revisited at each MRI and if her illness changes. **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers (2026), National Comprehensive Cancer Network
- TEMODAR (temozolomide) capsules, prescribing information (2026), U.S. National Library of Medicine, DailyMed (Merck Sharp & Dohme label)
- Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026), Aether Forge
- USPSTF A and B Recommendations (2026), U.S. Preventive Services Task Force
- Breast Cancer: Screening (2024), U.S. Preventive Services Task Force
- Cervical Cancer: Screening (2018), U.S. Preventive Services Task Force
- Colorectal Cancer: Screening (2021), U.S. Preventive Services Task Force
- Osteoporosis to Prevent Fractures: Screening (2025), U.S. Preventive Services Task Force
- Adult Immunization Schedule by Medical Condition and Other Indication (2026), Centers for Disease Control and Prevention

## Follow-up

- Cycle 2 of temozolomide on day 29 with a blood count first. Neuro-oncology review and MRI after cycle 2. Second zoster dose in one to two months; COVID-19 vaccine this season. Next preventive visit in one year. **S**

